skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 21 - 40 of 48  for All Library Resources

previous page 1 Results 2 3 next page
Refined by: New Records: New From Last Month remove subject: Heart remove
Result Number Material Type Add to My Shelf Action Record Details and Options
21
Electrophysiological phenotyping of left ventricular noncompaction cardiomyopathy in pediatric populations: A systematic review
Material Type:
Article
Add to My Research

Electrophysiological phenotyping of left ventricular noncompaction cardiomyopathy in pediatric populations: A systematic review

Physiological reports, 2024-05, Vol.12 (9), p.e16029-n/a [Peer Reviewed Journal]

2024 The Authors. published by Wiley Periodicals LLC on behalf of The Physiological Society and the American Physiological Society. ;2024 The Authors. Physiological Reports published by Wiley Periodicals LLC on behalf of The Physiological Society and the American Physiological Society. ;2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;EISSN: 2051-817X ;DOI: 10.14814/phy2.16029 ;PMID: 38684446

Full text available

22
Australia : Government adds two new heart disease treatments on the PBS
Material Type:
Newsletter Article
Add to My Research

Australia : Government adds two new heart disease treatments on the PBS

MENA Report, 2024

2022 Al Bawaba (Albawaba.com) Provided by SyndiGate Media Inc. (Syndigate.info). ;EISSN: 2219-0112

Digital Resources/Online E-Resources

23
Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy
Material Type:
Article
Add to My Research

Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy

European Heart Journal, 2023-11, Vol.44 (44)

public

Digital Resources/Online E-Resources

24
The effect of obesity and subsequent weight reduction on cardiac morphology and function in cats
Material Type:
Article
Add to My Research

The effect of obesity and subsequent weight reduction on cardiac morphology and function in cats

Digital Resources/Online E-Resources

25
New Cardiomyopathy Guidelines Endorse Cardiac Myosin Inhibitors, Expanded Role for Exercise
Material Type:
Article
Add to My Research

New Cardiomyopathy Guidelines Endorse Cardiac Myosin Inhibitors, Expanded Role for Exercise

HCPLive, 2024-05

Copyright MultiMedia Healthcare Inc. 2024 ;ISSN: 2767-7168 ;EISSN: 2767-7168

Digital Resources/Online E-Resources

26
Health Care Roundup: Market Talk
Material Type:
Newsletter Article
Add to My Research

Health Care Roundup: Market Talk

Dow Jones Institutional News, 2024

Copyright Dow Jones & Company Inc. May 14, 2024

Digital Resources/Online E-Resources

27
Health Care Roundup: Market Talk
Material Type:
Newsletter Article
Add to My Research

Health Care Roundup: Market Talk

Dow Jones Institutional News, 2024

Copyright Dow Jones & Company Inc. May 14, 2024

Digital Resources/Online E-Resources

28
Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)
Material Type:
Newsletter Article
Add to My Research

Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)

Business Wire, 2024

Copyright Business Wire 2024

Digital Resources/Online E-Resources

29
Press Release: Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)
Material Type:
Newsletter Article
Add to My Research

Press Release: Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)

Dow Jones Institutional News, 2024

Copyright Dow Jones & Company Inc. May 6, 2024

Digital Resources/Online E-Resources

30
"We want to see if the defibrillator reduces the risk of sudden death in patients with cardiac scarring."
Material Type:
Newsletter Article
Add to My Research

"We want to see if the defibrillator reduces the risk of sudden death in patients with cardiac scarring."

CE Noticias Financieras, 2024

CE Noticias Financieras English, Latin America - Distributed by ContentEngine LLC

Digital Resources/Online E-Resources

31
"Most arrhythmias can be treated with ablation."
Material Type:
Newsletter Article
Add to My Research

"Most arrhythmias can be treated with ablation."

CE Noticias Financieras, 2024

CE Noticias Financieras English, Latin America - Distributed by ContentEngine LLC

Digital Resources/Online E-Resources

32
Exercise, New Drug Class Recommended for Management of Hypertrophic Cardiomyopathy
Material Type:
Newsletter Article
Add to My Research

Exercise, New Drug Class Recommended for Management of Hypertrophic Cardiomyopathy

Targeted News Service, 2024

Targeted News Service

Digital Resources/Online E-Resources

33
Tenaya Therapeutics (TNYA: $4.25) drops 3.4% on increasing volatility; reports Loss of $32.2m; -15c [3.4%]
Material Type:
Newsletter Article
Add to My Research

Tenaya Therapeutics (TNYA: $4.25) drops 3.4% on increasing volatility; reports Loss of $32.2m; -15c [3.4%]

News Bites US - NASDAQ, 2024

Copyright News Bites Pty Ltd May 16, 2024

Digital Resources/Online E-Resources

34
Tenaya Therapeutics (TNYA: $4.39) inches higher, resistance at 12-day EMA; +11c [2.6%]
Material Type:
Newsletter Article
Add to My Research

Tenaya Therapeutics (TNYA: $4.39) inches higher, resistance at 12-day EMA; +11c [2.6%]

News Bites US - NASDAQ, 2024

Copyright News Bites Pty Ltd May 15, 2024

Digital Resources/Online E-Resources

35
Tenaya Therapeutics (TNYA: $4.28) lifts 1.9%; +8c [1.9%]
Material Type:
Newsletter Article
Add to My Research

Tenaya Therapeutics (TNYA: $4.28) lifts 1.9%; +8c [1.9%]

News Bites US - NASDAQ, 2024

Copyright News Bites Pty Ltd May 14, 2024

Digital Resources/Online E-Resources

36
Weekly: Tenaya Therapeutics (TNYA: $4.20) tumbles 10% on weak volume; -48c [10.3%]
Material Type:
Newsletter Article
Add to My Research

Weekly: Tenaya Therapeutics (TNYA: $4.20) tumbles 10% on weak volume; -48c [10.3%]

News Bites US - NASDAQ, 2024

Copyright News Bites Pty Ltd May 13, 2024

Digital Resources/Online E-Resources

37
Tenaya Therapeutics (TNYA: $4.20) tumbles 6.2%; -28c [6.2%]
Material Type:
Newsletter Article
Add to My Research

Tenaya Therapeutics (TNYA: $4.20) tumbles 6.2%; -28c [6.2%]

News Bites US - NASDAQ, 2024

Copyright News Bites Pty Ltd May 11, 2024

Digital Resources/Online E-Resources

38
Tenaya Therapeutics (TNYA: $4.48) decreases; -3c [0.7%]
Material Type:
Newsletter Article
Add to My Research

Tenaya Therapeutics (TNYA: $4.48) decreases; -3c [0.7%]

News Bites US - NASDAQ, 2024

Copyright News Bites Pty Ltd May 10, 2024

Digital Resources/Online E-Resources

39
Tenaya Therapeutics (TNYA: $4.51) falls 2.2%; -10c [2.2%]
Material Type:
Newsletter Article
Add to My Research

Tenaya Therapeutics (TNYA: $4.51) falls 2.2%; -10c [2.2%]

News Bites US - NASDAQ, 2024

Copyright News Bites Pty Ltd May 9, 2024

Digital Resources/Online E-Resources

40
Tenaya Therapeutics (TNYA: $4.61) lifts 1.5%; +7c [1.5%]
Material Type:
Newsletter Article
Add to My Research

Tenaya Therapeutics (TNYA: $4.61) lifts 1.5%; +7c [1.5%]

News Bites US - NASDAQ, 2024

Copyright News Bites Pty Ltd May 8, 2024

Digital Resources/Online E-Resources

Results 21 - 40 of 48  for All Library Resources

previous page 1 Results 2 3 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Refine My Results

Creation Date 

From To

Searching Remote Databases, Please Wait